| Title |
|
Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. |
|
|
| Publication Date |
|
| Author(s) |
|
| Subject |
|
programmed death-1 inhibition |
|
|
| Type of document |
|
| DOI |
|
| Abstract |
|
Dermatological toxicity is one of the most commonly reported immune-related adverse events in patients receiving checkpoint inhibitor immunotherapy. We report the gradual development of a widespread bullous pemphigoid-like reaction in a metastatic melanoma patient 8 months after commencing treatment with the programmed-death-1 (PD-1) inhibitor pembrolizumab, requiring prolonged corticosteroid therapy. This case highlights the potential for insidious and late development of severe cutaneous toxicity following PD-1 inhibitor therapy and suggests that even prolonged immunosuppression may not necessarily compromise the efficacy of PD-1 inhibition in advanced melanoma. |
|
|
| Link |
|
| Citation |
|
The Australasian journal of dermatology 2017; 58(3): e109-e112 |
|
|
| Jornal Title |
|
The Australasian journal of dermatology |
|
|
